This GR–ER crosstalk manifested as the improved relapse-free survival of breast cancer patients with ER-positive tumours, and GR was related to a favourable prognosis, while low GR expression was associated with worse outcomes, such as high Ki67, p53, and CD71 expression [35,40]. The gene discussed is NR3C1; the disease is breast carcinoma.